ovarian epithelial cancer
Recently Published Documents


TOTAL DOCUMENTS

123
(FIVE YEARS 27)

H-INDEX

20
(FIVE YEARS 2)

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Shiori Watabe ◽  
Sayaka Kobayashi ◽  
Mizuho Hatori ◽  
Yoshimi Nishijima ◽  
Naoki Inoue ◽  
...  

2021 ◽  
Vol 8 (1) ◽  
pp. 31-38
Author(s):  
Najme Nikdel ◽  
Javad Baharara ◽  
Saeed Zakerbostanabad ◽  
Maryam Tehranipour ◽  
◽  
...  

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Maryam Yahyaie ◽  
Majid Morovati-Sharifabad ◽  
Elham Salehi ◽  
Fatemeh Sarkargar ◽  
Gholamhosein Pourghanbari

Background: Ovarian cancer is the second leading cause of death in Iran compared with other gynecological diseases. Considering the role of cyclooxygenase (COX) enzymes and prostaglandin E2 production in tumor lesions, nonsteroidal anti-inflammatory drugs (NSAIDs) show antitumor properties by inhibiting COX. Furthermore, some compounds can serve as non-selective inhibitors of COX (such as ketoprofen) and prevent cancer development. Human epididymis protein 4 (HE4) is one of the most sensitive tumor markers known in the study of the disease of ovarian epithelial cancer. The expression of HE4 increases in different types of ovarian cancer. Objectives: The aim of this study was to determine the anti-cancer effects of ketoprofen on the viability of ovarian cancer cells and expression of HE4 gene. Methods: To calculate half-maximal inhibitory concentration (IC50), A2780S cells were treated with different concentrations of ketoprofen for 24 hours, then the cells were incubated with appropriate concentrations of IC50 for 24, 48, and 72 hours. Real-time polymerase chain reaction (PCR) was used to measure changes caused by the effect of drugs on HE4 gene expression and analyzed by the 2-ΔΔCT method. Results: The IC50 level of ketoprofen for 24 hours was 583.7 μM. According to real-time PCR results, treatment of cells with ketoprofen reduced HE4 expression. Conclusions: HE4 gene expression decreased in cells treated with ketoprofen compared with the cells in the control group, which proves the anti-cancer activity of ketoprofen and a reduction in the viability of ovarian cancer cells.


2020 ◽  
Vol 13 (4) ◽  
pp. 304-311
Author(s):  
A Iosifovna Yurcovskaya ◽  
Yulia Alex Stepanova ◽  
Dmitrii V Kalinin ◽  
Ilia A Kozlov

Cancer of the fallopian tube is a rare and difficult condition to be treated. It is often clinically simulated by ovarian epithelial cancer or primary ovarian and peritoneal carcinomas. Most of relapses in these tumors are observed in the small pelvis. Extrapelvic relapses and metastases to other organs are rather uncommon. Surgical cytoreduction and platinum-based chemotherapy are the mainstay of treatment.The authors present a rare and noteworthy clinical case of recurrence of high-grade serous carcinoma of the right fallopian tube involving the caecum dome and rectum in a 65-year-old female patient. There was demonstrated the choice of surgical treatment tactics in this clinical case that allowed obtaining a 62-month survival result.


Sign in / Sign up

Export Citation Format

Share Document